Robert C. Doebele, MD, PhD
Robert C. Doebele, MD, PhD
University of Colorado, Anschutz Medical Campus
Verified email at - Homepage
Cited by
Cited by
Crizotinib in ROS1-rearranged non–small-cell lung cancer
AT Shaw, SHI Ou, YJ Bang, DR Camidge, BJ Solomon, R Salgia, GJ Riely, ...
New England Journal of Medicine 371 (21), 1963-1971, 2014
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
A Drilon, TW Laetsch, S Kummar, SG DuBois, UN Lassen, GD Demetri, ...
New England Journal of Medicine 378 (8), 731-739, 2018
Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non–small cell lung cancer
RC Doebele, AB Pilling, DL Aisner, TG Kutateladze, AT Le, AJ Weickhardt, ...
Clinical cancer research 18 (5), 1472-1482, 2012
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
AT Shaw, BY Yeap, BJ Solomon, GJ Riely, J Gainor, JA Engelman, ...
The lancet oncology 12 (11), 1004-1012, 2011
Non–small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology
DS Ettinger, DE Wood, DL Aisner, W Akerley, J Bauman, LR Chirieac, ...
Journal of the National Comprehensive Cancer Network 15 (4), 504-535, 2017
Rociletinib in EGFR-mutated non–small-cell lung cancer
LV Sequist, JC Soria, JW Goldman, HA Wakelee, SM Gadgeel, A Varga, ...
New England Journal of Medicine 372 (18), 1700-1709, 2015
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic …
DR Gomez, GR Blumenschein Jr, JJ Lee, M Hernandez, R Ye, ...
The lancet oncology 17 (12), 1672-1682, 2016
Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non–small-cell lung cancer
AJ Weickhardt, B Scheier, JM Burke, G Gan, X Lu, PA Bunn Jr, DL Aisner, ...
Journal of Thoracic Oncology 7 (12), 1807-1814, 2012
Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer
A Vaishnavi, M Capelletti, AT Le, S Kako, M Butaney, D Ercan, S Mahale, ...
Nature medicine 19 (11), 1469-1472, 2013
Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1)
A Drilon, S Siena, SHI Ou, M Patel, MJ Ahn, J Lee, TM Bauer, AF Farago, ...
Cancer discovery 7 (4), 400-409, 2017
Identifying and targeting ROS1 gene fusions in non–small cell lung cancer
KD Davies, AT Le, MF Theodoro, MC Skokan, DL Aisner, EM Berge, ...
Clinical Cancer Research 18 (17), 4570-4579, 2012
Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non–small-cell lung cancer: long-term results of a multi-institutional …
DR Gomez, C Tang, J Zhang, GR Blumenschein Jr, M Hernandez, JJ Lee, ...
Journal of Clinical Oncology 37 (18), 1558, 2019
Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment
DR Camidge, SA Kono, A Flacco, AC Tan, RC Doebele, Q Zhou, L Crino, ...
Clinical Cancer Research 16 (22), 5581-5590, 2010
TRKing down an old oncogene in a new era of targeted therapy
A Vaishnavi, AT Le, RC Doebele
Cancer discovery 5 (1), 25-34, 2015
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
RC Doebele, A Drilon, L Paz-Ares, S Siena, AT Shaw, AF Farago, ...
The Lancet Oncology 21 (2), 271-282, 2020
Molecular pathways: ROS1 fusion proteins in cancer
KD Davies, RC Doebele
Clinical cancer research 19 (15), 4040-4045, 2013
Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers
CM Blakely, TBK Watkins, W Wu, B Gini, JJ Chabon, CE McCoach, ...
Nature genetics 49 (12), 1693-1704, 2017
An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101
RC Doebele, LE Davis, A Vaishnavi, AT Le, A Estrada-Bernal, S Keysar, ...
Cancer discovery 5 (10), 1049-1057, 2015
Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed
DR Camidge, SA Kono, X Lu, S Okuyama, AE Barón, AB Oton, AM Davies, ...
Journal of Thoracic Oncology 6 (4), 774-780, 2011
Oncogene status predicts patterns of metastatic spread in treatment‐naive nonsmall cell lung cancer
RC Doebele, X Lu, C Sumey, DLA Maxson, AJ Weickhardt, AB Oton, ...
Cancer 118 (18), 4502-4511, 2012
The system can't perform the operation now. Try again later.
Articles 1–20